Miranda Schmalfuhs

Miranda Schmalfuhs is a journalist who covers the pharmaceutical industry. She has written extensively about the impact of new drugs and technologies on healthcare, with a focus on weight-loss medications and GLP-1 drugs. Her work appears in Pharm Exec and Pharmaceutical Executive, where she reports on developments in the pharma industry for readers interested in staying up to date with the latest news.

Biography:  https://www.pharmexec.com/authors/miranda-schmalfuhs

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

  • In the article, governments are expressing concerns about how they would pay for widespread GLP-1 drug usage among their populations.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

95%

Examples:

  • Governments are expressing concerns about how they would pay for widespread GLP-1 drug usage among their populations.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

GLP-1: A Game Changer in Obesity Therapy and Beyond

GLP-1: A Game Changer in Obesity Therapy and Beyond

Broke On: Saturday, 15 June 2024 GLP-1, a satiety hormone discovered in groundbreaking research, shows promise for obesity therapy and type 2 diabetes remission. GLP-1 drugs have led to weight loss and improved cardiovascular health, despite some side effects. Ongoing research aims to enhance their efficacy and expand their applications beyond obesity.